NEW YORK, July 16 (Reuters) - The malaria drug touted by U.S. President Donald Trump as a COVID-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.
About 24% of the patients given hydroxychloroquine in the study had persisting symptoms over a 14-day period, while roughly 30% of the group given a placebo were determined to have persistent symptoms over the same period.
The difference was not statistically significant, the researchers said.
“Hydroxychloroquine did not substantially reduce symptom severity or prevalence over time in non-hospitalized persons with early COVID-19,” the researchers wrote in an article to be published by Annals of Internal Medicine on Thursday.
The randomized, placebo-controlled study was conducted on 491 non-hospitalized patients. Owing to test shortages in the United States, only 58% of participants were tested for the disease.
The study “provides strong evidence that hydroxychloroquine offers no benefit in patients with mild illness”, Dr. Neil Schluger, of New York Medical College, said in an editorial on the study, also scheduled to be published on Thursday.
Reporting by Michael Erman Editing by David Goodman
Our Standards: The Thomson Reuters Trust Principles.